Objectives: To investigate the optimal timing for post-chemoradiotherapy (CRT) reference magnetic resonance imaging (MRI) in head and neck cancer, so as to demonstrate a maximal treatment response. To assess whether this differs in human papillomavirus–related oropharyngeal cancer (HPV-OPC) and whether the MRI timing impacts on the ability to predict treatment success. Methods: Following ethical approval and informed consent, 45 patients (40 male, mean age 59.7 ± 7.9 years, 33 HPV-OPC) with stage 3 and 4 HNSCC underwent pre-treatment, 6- and 12-week post-CRT MRIs in this prospective cohort study. Primary tumour (n = 39) size, T2w morphology and diffusion weight imaging (DWI) scores, together with nodal (n = 42) size and necrotic/cystic change, were recorded. Interval imaging changes were analysed for all patients and according to HPV-OPC status. MRI descriptors and their interval changes were also compared with 2-year progression-free survival (PFS). Results: All MRI descriptors significantly changed between pre-treatment and 6-week post-treatment MRI studies (p
CITATION STYLE
Connor, S. E. J., Burd, C., Sivarasan, N., & Goh, V. (2021). MRI in head and neck cancer following chemoradiotherapy: what is the optimal delay to demonstrate maximal response? European Radiology, 31(12), 9273–9286. https://doi.org/10.1007/s00330-021-07913-x
Mendeley helps you to discover research relevant for your work.